Arix Bioscience PLC: Annual Results 2017
April 23, 2018 02:01 ET
|
Arix Bioscience PLC
Annual Results 2017 LONDON, 23 April 2018: Arix Bioscience plc (LSE:ARIX) ("Arix Bioscience", "Arix" or the "Company"), a global life sciences company supporting medical innovation, today...
Arix Bioscience PLC: CEO Letter to Shareholders
January 04, 2018 09:02 ET
|
Arix Bioscience PLC
CEO Letter to Shareholders LONDON, 4 January 2018: As 2018 gets underway, I would like to reflect on Arix Bioscience plc's (LSE: ARIX) ("Arix Bioscience" or "Arix") first year as a public...
Arix Bioscience PLC: Arix Bioscience co-leads $30 million financing for Aura Biosciences
December 21, 2017 07:00 ET
|
Arix Bioscience PLC
Arix Bioscience co-leads $30 million financing for Aura Biosciences Funding to advance development of Aura's novel treatment to selectively destroy cancer cells; lead candidate AU-011 currently...
Arix Bioscience leads $30 million financing for Atox Bio
December 04, 2017 07:01 ET
|
Arix Bioscience PLC
Arix Bioscience leads $30 million financing for Atox Bio Funding to advance Reltecimod into a Phase 2 clinical study for acute kidney injury, building upon Atox Bio's on-going Phase 3 clinical...
Arix Bioscience notes Harpoon Therapeutics' immuno-oncology collaboration with AbbVie
October 18, 2017 08:33 ET
|
Arix Bioscience PLC
Arix Bioscience notes Harpoon Therapeutics' immuno-oncology collaboration with AbbVie LONDON, 18 October 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare and life...
Arix Bioscience PLC: Appoints Giles Kerr to Board of Directors
October 17, 2017 07:00 ET
|
Arix Bioscience PLC
Arix Bioscience appoints Giles Kerr to Board of Directors LONDON, 17 October 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science...
Arix Bioscience notes positive Phase I clinical and non-clinical data from Amplyx for the treatment of life-threatening fungal infections
October 10, 2017 07:00 ET
|
Arix Bioscience PLC
Arix Bioscience notes positive Phase I clinical and non-clinical data from Amplyx for the treatment of life-threatening fungal infections LONDON, 10 October 2017: Arix Bioscience plc (LSE: ARIX)...
Arix Bioscience participates in $80 million Series C financing for Autolus
September 26, 2017 07:00 ET
|
Arix Bioscience PLC
Arix Bioscience participates in $80 million Series C financing for Autolus LONDON, 26 September 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "Arix"), a global healthcare and life...
Arix Bioscience plc notes positive clinical study announcements from Autolus Limited
September 18, 2017 07:00 ET
|
Arix Bioscience PLC
Arix Bioscience plc notes positive clinical study announcements from Autolus Limited LONDON, 18 September 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare and life...
Arix Bioscience plc notes positive trial data from Verona Pharma in COPD
September 07, 2017 09:05 ET
|
Arix Bioscience PLC
Arix Bioscience plc notes positive trial data from Verona Pharma in COPD LONDON, 7 September 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare and life science...